Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy‐Based Cross‐Sectional Survey
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Katrine Kjærgaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Pharmacy Funen, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Aims
Users of semaglutide for weight management (SEMA‐WM) may not follow the recommended treatment regimen. We investigated SEMA‐WM treatment patterns among Danish adult users.
Methods
A questionnaire‐based survey was conducted across 28 Danish community pharmacies between March and May 2025. Adults redeeming a SEMA‐WM prescription were invited to participate, with first‐time users invited to a follow‐up survey after 6 months.
Results
Of 1470 individuals invited, 767 (52%) completed the questionnaire. Forty‐five percent used 1 mg as their current dose, and 8% expected to reach 2.4 mg. Ten percent reported dosing SEMA‐WM by “counting clicks” on the injection pen, in contrast with official prescribing guidelines. Users treated for 1–3 months reported a median weight loss of 6% (IQR 3–7), increasing to 12% (IQR 9–14), 17% (IQR 12–21), and 20% (IQR 15–26) for those treated for 3–6 months, 6–12 months, and > 1 year, respectively. Weight loss by treatment duration was similar among 1 mg users. Twenty‐four percent reported reduced/discontinued concomitant medication use following SEMA‐WM initiation, especially for muscle/joint pain (30%) and antihypertensives (24%). Reduced/discontinued medication use was similar among 1 mg users. Among 42 first‐time users, 83% were still using SEMA‐WM after 6 months, usually 1 mg (60%). Among users who had discontinued treatment (17%), side effects were the most reported reason.
Conclusions
Many SEMA‐WM users remained on 1 mg and reported weight loss and medication reductions similar to the overall cohort. Findings indicate that some users appear to obtain the desired effect at 1 mg, underscoring the need for better guidance on individualized treatment trajectories.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
- Novo Nordisk A/S, Copenhagen, Denmark.
ORCID-Profile: Katrine Kjærgaard, Trine Graabæk, Reimar W Thomsen, Lise Gehrt Cardél, Maja Bramming, Anton Pottegård, Carina Lundby
Förderung
- Novo Nordisk
Zitieren
APA
Kjærgaard, K., Graabæk, T., Thomsen, R. W., Cardél, L. G., Bramming, M., Pottegård, A., & Lundby, C. (2026). Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy‐Based Cross‐Sectional Survey. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71099
Vancouver
Kjærgaard K, Graabæk T, Thomsen RW, Cardél LG, Bramming M, Pottegård A, et al. Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy‐Based Cross‐Sectional Survey. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71099
BibTeX
@article{Kjrgaard2026,
author = {Kjærgaard, Katrine and Graabæk, Trine and Thomsen, Reimar W and Cardél, Lise Gehrt and Bramming, Maja and Pottegård, Anton and Lundby, Carina},
title = {Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy‐Based Cross‐Sectional Survey},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71099}
}
EUVIMED